Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of IDE849 (SHR4849), a potential first-in-class Phase 1 DLL3 TOP1i antibody drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NETs).

Next Previous
Trial Profile

Phase 1 study of IDE849 (SHR4849), a potential first-in-class Phase 1 DLL3 TOP1i antibody drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NETs).

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDE 161 (Primary) ; SHR 4849 (Primary)
  • Indications Neuroendocrine tumours; Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 22 Jul 2025 According to an IDEAYA Biosciences media release, this U.S. phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025.
  • 06 May 2025 According to an IDEAYA Biosciences media release, the clinical data from this trial is anticipated in the second half of 2025.
  • 21 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top